Apparatus and method for intra-cardiac mapping and ablation

Information

  • Patent Grant
  • 9119634
  • Patent Number
    9,119,634
  • Date Filed
    Tuesday, November 18, 2014
    9 years ago
  • Date Issued
    Tuesday, September 1, 2015
    8 years ago
Abstract
An intra-cardiac mapping system is based on locating the ports through which blood flows in or out of the heart chambers. For many procedures, such as ablation to cure atrial fibrillation, locating the pulmonary veins and the mitral valve accurately allows to perform a Maze procedure. The location of the ports and valves is based on using the convective cooling effect of the blood flow. The mapping can be performed by a catheter-deployed expandable net or a scanning catheter. The same net or catheter can also perform the ablation procedure.
Description
BACKGROUND

1. Technical Field


This disclosure generally relates to minimally invasive heart surgery, also known as percutaneous cardiac surgery and particularly relates to percutaneous mapping and ablation.


2. Description of the Related Art


Atrial fibrillation is a well known disorder in which spurious electrical signals cause an irregular heart beat. The disorder has a well known cure known as the Maze procedure, in which a border is ablated around the sources of the spurious signals, typically in the left atrium but sometimes in the right atrium. The procedure is very commonly performed under direct vision, but difficult to perform percutaneously via a catheter because of the associated risk. Any error in navigation inside the heart can cause fatal damage. The key to a percutaneous procedure is mapping of the inside of the right and left atrium. Access to the right atrium is simple via the superior vena cava; the left atrium can be reached by i) perforating the transatrial septum, ii) via the aorta and the left ventricle or iii) via the pulmonary veins.


Prior approaches to map the inside of the atrium relied on electrical activity picked up from the atrium wall. These approaches require intimate electrical contact, not always possible because of scar tissue and deposits. These approaches may fail to accurately map the edges of the openings where the veins enter the atrium; information that is useful for correct placement of the ablation pattern. Other mapping methods, such as using an array of ultrasonic transducers, are not practical since such arrays typically will not fit through a catheter of a reasonable size (8-10 mm diameter). A superior mapping apparatus and method, that enables safe execution of the Maze and other intra-cardiac procedures is desirable.


A good survey article on the subject is: “Ablation of Atrial Fibrillation: Energy Sources and Navigation Tools: A survey” by Ruediger Becker and Wolfgang Schoels (J. of Electrocardiology, Vol 37, 2004, pp 55-61). The article includes an extensive bibliography.


BRIEF SUMMARY

Embodiments of an intra-cardiac mapping system are based on locating openings or ports and values through which blood flows in or out of the heart chambers. For many procedures, such as ablation to cure atrial fibrillation, accurately locating the pulmonary veins and the mitral valve allows performance of a Maze procedure. The openings, ports and valves may be located based on the convective cooling effect of the blood flow. The mapping can be performed by a catheter-deployed expandable net or a scanning catheter. The same net or catheter can also perform the ablation procedure.


In one embodiment, a method for intra-cardiac mapping comprises: introducing a plurality of flow sensors into an intra-cardiac cavity; locating points in a wall forming said cavity based on sensing blood flow; and mapping said walls of said cavity based on said points. The method for intra-cardiac mapping may include said blood flow being sensed by its convective cooling effect on a heated sensor. The method for intra-cardiac mapping may include said sensing being done by a steerable linear array. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by RF ablation. The method for intra-cardiac mapping may include being used for treating atrial fibrillation by microwave ablation. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by cryogenic ablation. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by laser ablation. The method for intra-cardiac mapping may include said blood flow being sensed by the resistance change of a heated resistive wire.


In another embodiment, a method for intra-cardiac mapping comprises: introducing an expandable sensing mesh into said cavity via a catheter; using said mesh to locate openings in walls forming said cavity based on the convective heat transfer of blood flowing through said holes; and mapping inside of said cavity based on location of said openings. The method for intra-cardiac mapping may include said blood flow being sensed by its convective cooling effect on a heated sensor. The method for intra-cardiac mapping may include said sensing being done by a steerable linear array. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by RF ablation. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by microwave ablation. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by cryogenic ablation. The method for intra-cardiac mapping may include said mapping being used for treating atrial fibrillation by laser ablation. The method for intra-cardiac mapping may include said blood flow being sensed by the resistance change of a heated resistive wire. The method for intra-cardiac mapping may include said mesh comprising small coils of nickel wire wound on a mesh of a flexible insulator. The method for intra-cardiac mapping may include an electronic switch used to minimize the number of electrical wires passing through said catheter.


In yet another embodiment, a method for treating atrial fibrillation comprises: introducing at least one flow sensor into an intra-cardiac cavity; locating points in a wall forming said cavity based on sensing blood flow; mapping walls of said cavity based on said points; and ablating a pattern into walls of said cavity based on said mapping. The method for treating atrial fibrillation may include said blood flow being sensed by its convective cooling effect on a heated sensor. The method for treating atrial fibrillation may include said sensing being done by a steerable linear array. The method for treating atrial fibrillation may include said mapping being used for treating atrial fibrillation by RF ablation. The method for treating atrial fibrillation may include said mapping being used for treating atrial fibrillation by microwave ablation. The method for treating atrial fibrillation may include said mapping being used for treating atrial fibrillation by cryogenic ablation. The method for treating atrial fibrillation may include said mapping being used for treating atrial fibrillation by laser ablation. The method for treating atrial fibrillation may include said blood flow being sensed by the resistance change of a heated resistive wire. The method for treating atrial fibrillation may include said flow sensors also acting as electrodes for said ablation. The method for treating atrial fibrillation may include said flow sensor being based on temperature sensing and a same sensor being used to monitor temperature during said ablation. The method for treating atrial fibrillation may include said ablation being unipolar. The method for treating atrial fibrillation may include said ablation being bipolar. The method for treating atrial fibrillation may include said ablated pattern being a Maze procedure.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, identical reference numbers identify similar elements or acts. The sizes and relative positions of elements in the drawings are not necessarily drawn to scale. For example, the shapes of various elements and angles are not drawn to scale, and some of these elements are arbitrarily enlarged and positioned to improve drawing legibility. Further, the particular shapes of the elements as drawn, are not intended to convey any information regarding the actual shape of the particular elements, and have been solely selected for ease of recognition in the drawings.



FIG. 1 is a cross sectional view of the heart showing the mapping mesh deployed in the left atrium.



FIG. 2 is a cross sectional view of the sensing device.



FIGS. 3A and 3B are isometric views of the mesh in both folded and expanded positions.



FIG. 4 is an isometric enlarged view of a portion of the mesh.



FIG. 5 is an electrical schematic of a mapping and ablation system.



FIG. 6 is an electrical schematic of a simplified mapping system.



FIG. 7 is a schematic view of the display console of the system.



FIGS. 8A and 8B are graphical views of a mapping that illustrate an interpolation principle.



FIG. 9 is a cross sectional view of an alternate embodiment, using mechanical or manual scanning in one axis.



FIG. 10 is a cross sectional view of an alternate embodiment, using mechanical scanning in two dimensions.



FIG. 11 shows the use of the invention for bipolar ablation.





DETAILED DESCRIPTION


FIG. 1 shows a sensing and ablation mesh 7 inserted into a left atrium 3 of a heart 1 according to one illustrated embodiment.


By way of example, the mesh 7 may be delivered via a catheter 60 inserted via a superior vena cava 4 and penetrating a transatrial septum from a right atrium 2 of the heart 1. The mesh 7 is communicatively coupled to the rest of the system, for example, by electrical wires 6.


Before any ablation takes place, the inside of the left atrium 3 is mapped in order to locate the openings or ports 8 leading to the pulmonary veins 5, as well as the mitral valve 9. A typical Maze procedure ablates a “fence” around openings or ports 8 to stop propagation of spurious electrical signals which cause the heart 1 to contract at the wrong times.


The mapping may locate some or all of the openings or ports 8 through which blood flows in and out of the left atrium 3, as the Maze procedure is mainly concerned with the location of these openings or ports 8. By the way of example, in the left atrium 3, the four openings or ports 8 leading to the pulmonary veins 5 as well as the mitral valve 9 may be located. The location of these openings or ports 8 may be based on the fact that the convective cooling effect of the blood is significant, and a slightly heated mesh 7 pressed against the walls of the left and/or right atrium 3, 2 will be cooler at the areas which are spanning the openings or ports 8 carrying blood.



FIG. 2 shows the ablation mesh 7 covered by miniature heating and/or temperature sensing elements 10a-10c flow (collectively 10, only three illustrated in the figure). Each one of these elements 10a-10c comprises a few turns of a resistive wire, for example nickel wire, wound on an electrically insulated mesh. A low current is passed through each element 10, raising a temperature of the element 10 by about 1 degree C. above normal blood temperature. A first element 10b, which lies across an opening or port 8 of one of the pulmonary veins 5, will be cooled by blood flow. The other elements are against a wall 3 and hence do not lie across any of the openings or ports 8.


By identifying the relatively cooler elements 10a, 10c on the mesh 7, the location of the openings or ports 8 may be found.


This method does not require intimate contact with the wall 3, as the cooling effect is significant even a few millimeters away from the opening.


The same elements 10 can be used as ablation electrodes during an ablation stage. It was found that the power required to raise the temperature of the mesh 7 by a small but easily detectable amount is very small, on the order of 10-50 mW per element 10. If the elements 10 are made of a material that has a significant change in resistance with temperature, the temperature drop can be sensed by measuring a voltage across the element 10 when driven by a constant current. A good choice for element material is nickel wire, which is inert, highly resistive and has a significant temperature coefficient of resistance (about 0.6% per deg C.). Since the resistance of the elements 10 is low (typically 0.1-1 ohm), the electrical noise is very low and temperature changes as low as 0.1 deg can be easily detected. For even higher detection sensitivity, the voltage waveform can be sampled in synchronization with the heart rate or the average voltage removed and only the change amplified. Such methods are referred to as “AC coupling”. A further refinement to reduce the electrical noise is to pass the signal through a digital band pass filter having a center frequency tracking the heart rate. To avoid any potential tissue damage, the temperature of the elements 10 of the mesh 7 is only slightly above the blood temperature, typically 0.1-3 degrees C. above blood temperature.



FIG. 3A shows the mesh 7 in a compressed configuration “A” and FIG. 3B shows the mesh 7 in an expanded configuration “B”. Since the mesh 7 has to fit into a catheter 60, the mesh 7 should be very flexible. Besides elements 10 discussed earlier, there is also a large number of leads 13 coming out of the mesh 7. Leads 13 can be loose, as shown in FIG. 3B, or may be bonded to the mesh 7. To avoid feeding a large number of wires all the way to an operating console, an electronic selector switch may be employed, which may, for example, be mounted in the catheter 60. This reduces the number of electrical wires from over 100 to about 10. The mesh 7 can be self-expanding (elastic) or balloon-expandable. Self expanding allows normal blood flow during the procedure. For balloon expandable devices, the expansion balloon should be removed before the mapping, to avoid blocking the flow of blood.



FIG. 4 shows the mesh 7 in more detail. Insulated longitudinal (i.e., parallel to catheter) wires 25 are crossed by cross wires 26. Each section of the mesh 7 is covered by a few turns of thin (0.05-0.2 mm) nickel wire 10 having leads 13. The leads 13 can be regular thin copper wire. The longitudinal wires 25 can be stiffer than the cross wires 26, therefore can be made self-expanding by incorporating a core 14 made of coiled flexible metal wire such as Nitinol. A metallic core may interfere with the ablation process at higher frequencies and can be replaced by simply making the longitudinal wires 25 of a polymeric material thicker than the cross wires 26. The cross wires 26, which may form rings around wires 25, should be very flexible to compress into the catheter 60. The cross wires 26 could incorporate a very thin wire or coiled up wire. Use of a flexible mesh 7 not only allows percutaneous delivery, but also permits the mesh 7 to follow the atrial volume change each heartbeat. The mesh 7 should stay in contact with or close to the atrial wall during the cardiac cycle, otherwise the measurement and the ablation may only be performed during parts of the cardiac cycle. The diameter of the longitudinal wires 25 and cross wires 26 are typically 0.2-1 mm. The mesh 7 may include about 10-20 longitudinal wires 25 and about 10-20 cross wires 26. The insulation can be any polymeric material such as thin enamel or polymer coating. Practically any polymer can be used, as the maximum temperature it will be subject to, including during the ablation phase, is around 100 degrees C.



FIG. 5 shows an electrical system, according to one illustrated embodiment. The elements 10 may be resistive heaters wound on the mesh 7. Each of the elements 10 is connected by electronic element switches 15 (typically FET or MOS-FET type) to a single pair of wires leading out of the body to a mode selection switch 17. Element switches 15 are selected by de-multiplexer or selector 16. The de-multiplexer or selector 16 is controlled by a small number of wires or even a single wire if data is sent in serial form, by a multiplexer 22. Element switches 15 and de-multiplexer or selector 16 may be built into the catheter 60, which may, for example, be located near the point of deployment of the mesh 7. The element switches 15 have to carry significant power during the ablation phase.


The mode selection 17 selects between a mapping mode (position shown in the drawing) and an ablation mode (second position of switch). In the mapping mode, a current is created by a voltage source 18 and resistor 19 (e.g., forming a constant current source) and routed into a selected element 10 by the element switches 15. For each measurement, the two element switches 15 that are connected to the scanned element 10 are in an enabled state (ON), the rest of the element switches being in a disabled state (OFF). The voltage drop across an element 10 is measured by an analog to digital (A/D) converter 20 and fed to a control computer 23. For greater accuracy, four terminal sensing can be employed. In a preferred embodiment, the detection is AC coupled, therefore the DC voltage drops along the wires are of no consequence, and no four-terminal sensing is needed. For AC coupling, the control computer 23 includes a 0.5 Hz low pass filter implemented in software. The slight disadvantage of the AC coupled method approach is speed, as the low signal frequency (e.g., about 1 Hz), requires a few seconds per measurement. Other temperature sensors and/or approaches, such as thermistors or thermocouples, can be used in conjunction with the elements 10. Mapping is achieved by turning on all of the elements 10 sequentially and measuring the temperature of each. A map is formed in the control computer 23 and the lower temperature spots on the mesh correspond to the openings or ports 8 leading to the veins or valves.


When the mode selection switch 17 is in the ablation mode, a generator 21 (e.g., Radio Frequency (RF)) is connected (e.g., sequentially) to selected elements 10 by the control computer 23 addressing the multiplexer 22 which controls the element switches 15 via the de-multiplex selector 16. The complete operation, including scanning and ablation, can be completed in less than 5 minutes. The configuration illustrated in FIG. 5 implies unipolar ablation; however bipolar ablation can be used as well and is discussed below. Clearly other sources of ablation can be used besides RF. Frequencies from DC to microwaves can be used, as well as delivery of laser power via optical fibers or cryogenics via thin tubes. For laser ablation element switches 15 are optical switches, while for cryogenic ablation the element switches 15 are valves.


During ablation it is desirable to monitor the temperature of the mode selection switch 17 to the mapping position several times during the ablation procedure. The measured temperatures can be displayed on a display 32 (FIG. 7). RF ablation is typically performed at frequencies of 100 KHz-1 MHz and power levels which depend on the size of the elements 10, but can be as high as 100 W. Various RF ablation techniques and equipment are well known in the art.



FIG. 6 shows an embodiment in which the mapping system is separate from the ablation system. In this system, the mesh 7 has very few connecting wires. As illustrated, each longitudinal wire 25 has a single output wire and each cross wire 26 has a single output wire 13. For a 10×10 mesh 7 with 100 nodes, only twenty-one wires are needed (ten plus ten plus ground wire), instead of two hundred wires. This allows all wires to be brought directly out of the catheter 60. This also allows placement of selector switches 16 and 24 together with the control system. For example, if the element marked as “A” is selected; a current is selected to run through the longitudinal wire 25 which includes element A. The voltage drop is sensed by the two circumferential wires 13 that connect directly to A. Since no current flows in the other elements at the time of measurement, the voltage drop is only caused by element A. It is sensed by A/D converter 20 via double pole selector 24.


After a map is established, it is displayed on a display screen 32 as shown in FIG. 7. The surgeon can select which elements 10 will cause tissue ablation in the atrium. The pattern formed is along the line of the standard Maze procedure. The location of the pulmonary veins 5 and the mitral valve 9 is inferred from the temperature date and drawn on the display screen.



FIGS. 8A and 8B demonstrate the principle of accurate location of the veins and valves even if the grid is relatively coarse. The exact location can be interpolated based on the fact that when only part of the element 10 is exposed to the blood flow. By the way of example, if the temperature of the mesh 7 is 1 degree C. above blood temperature and equals the blood temperature under normal blood flow (this was experimentally verified), the temperatures of a group of elements 10 will be as shown in FIG. 8A when aligned with the opening or port 8 of vein 5. The number near each element 10 is the temperature drop. When moved, some of the elements 10 will only be partially positioned in the flow path under vein 5, as shown by FIG. 8B. The temperatures of those elements 10 will be between 0 and 1 degree above blood temperature. The exact temperature drop between 0 to 1 corresponds with the exact shift. This allows accurate determination of the location and size of each opening or port 8, data used by the control computer 23 to draw the map shown in FIG. 7. A grid spacing of 10 mm allows about 1 mm accuracy.


An alternative to a full mesh is a partial mesh, or even a single sensor, that is mechanically scanned across the area to be mapped. FIG. 9 shows a linear sensor array 27 pushed into the atrium 2 via vein 4 by the catheter 60. The linear sensor array 27 has a linear array of elements 10 similar to those used in the full mesh 7. After a linear mapping is performed the linear sensor array 27 is rotated (as shown by broken line 27′) a small amount (10-20 degrees) by stem 11 (similar to electrical wires 6) and a new scan is performed. The same procedures previously described may be used for ablation.



FIG. 10 shows the use of a single steerable catheter 28 as a mapping and ablation tool. Steerable catheters are controlled remotely by mechanical, magnetic, hydraulic or other means. A steerable catheter 28 can be used to scan the inside of the atrium 3 by bending, as shown in broken line 28′. The location is monitored by external or internal sensors. A position of a tip of the steerable catheter 28 can also be monitored by fluoroscopy. The catheter tip contains a heating and/or ablation element 10. Steerable catheters 28 may advantageously carry a wide range of ablation systems, since only one connection and one point are needed.


A full mesh trades a higher complexity for better speed and accuracy when compared to linear arrays or single point scanning.


The previous examples were of unipolar ablation, with the ablation current returning to ground via the patient's body. The disclosed system can also be used for bipolar ablation as shown in FIG. 11. In unipolar ablation the same voltage is connected to both leads 13 and 13′ of an element 10. In bipolar ablation the voltage is connected to lead 13 while the other end, 13′, is grounded. It is important that the element 10 will be of sufficient resistance to cause most of the ablation current to flow through heart tissue 1. Electrodes 30 make contact with tissue 1 while the wire used in the element 10 is covered by an insulator. The advantage of bipolar ablation is better control of ablation depth. Typical ablation temperatures are 60-80 degrees C. At a higher temperature the tissue 1 becomes less conductive, forcing the ablation current to seek a new path. This promotes full ablation of the tissue 1. The element 10 can also be designed to assist ablation by creating heat when ablation voltage is applied across it.


One possible advantage of at least some of the presently disclosed embodiments over electrical potential mapping methods is that the presently disclosed embodiments do not require perfect contact between the mesh 7 and the tissue 1. The presently disclosed embodiments may also advantageously be less sensitive to the surface properties of the tissue, such as scar tissue or plaque.


If the mesh is separated from the tissue by a thin layer of blood, both the temperature sensing and the ablation functions of the presently disclosed embodiments will still function properly.


The word “element” in this disclosure has to be interpreted in a broad sense as any element capable of sensing blood flow. Clearly the elements do not need to be heaters, as cooling elements will work equally well. If a material is injected into the blood flow, any sensor capable of detecting this material can be used to detect blood flow. By the way of example, if the blood is cooled or warmed slightly before returning to the heart only temperatures sensors are needed. Since temperature differences as low as 0.1 degree C. can be detected reliably, it is fairly simple to heat or cool the blood slightly before it returns to the heart (even by a simple external pad).


The above description of illustrated embodiments, including what is described in the Abstract, is not intended to be exhaustive or to limit the embodiments to the precise forms disclosed. Although specific embodiments of and examples are described herein for illustrative purposes, various equivalent modifications can be made without departing from the spirit and scope of the disclosure, as will be recognized by those skilled in the relevant art.


The various embodiments described above can be combined to provide further embodiments. Aspects of the embodiments can be modified, if necessary, to employ systems, circuits and concepts of the various patents, applications and publications to provide yet further embodiments.


These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

Claims
  • 1. A method executed by a control computer of a system, the system including an array of elements configured to be introduced into an intra-cardiac cavity, at least one of the elements configured at least to sense temperature, the control computer coupled to the array of elements, and the method comprising: locating points on a wall of the intra-cardiac cavity based on sensing blood flow with the elements;mapping the wall of the intra-cardiac cavity based on the located points to form a map presented by a display;updating the map while ablating a pattern into the wall of the intra-cardiac cavity with at least some of the elements; andmonitoring, with at least one of the at least one of the elements, temperature during each of the locating and the ablating,wherein each of the elements is responsive to convective heat transfer by the blood flow, and wherein the method further comprises providing a visual representation of one or more regions of the wall of the intra-cardiac cavity concurrently with each of one or more ports in a surface of the wall of the intra-cardiac cavity with respect to the one or more regions based at least on the sensed blood flow.
  • 2. The method of claim 1, wherein the sensing blood flow with the elements comprises a sensing of temperature with the elements.
  • 3. The method of claim 1, further comprising switching between a mapping mode, in which the mapping is performed, and an ablation mode in which the ablating is performed.
  • 4. The method of claim 3, further comprising repeatedly switching between the mapping mode and the ablation mode during the ablating.
  • 5. The method of claim 1, further comprising including the visual representation in the map presented by the display.
  • 6. The method of claim 1, wherein the sensing blood flow includes receiving signals that are indicative of convective heat transfer by the blood flow.
  • 7. The method of claim 1, wherein the ablating includes providing current to at least one element of the at least some of the elements that is proximate to one of the one or more ports in the surface of the wall of the intra-cardiac cavity, wherein the one of the one or more ports is provided by a port of a pulmonary vein in the surface of the wall of the intra-cardiac cavity.
  • 8. The method of claim 1, wherein the elements are arranged on a structure of the system, and the structure is expandable between a compressed configuration and an expanded configuration, and wherein the method further comprises percutaneously delivering the elements to the intra-cardiac cavity in the compressed configuration.
  • 9. The method of claim 8, further comprising expanding the structure into the expanded configuration within the intra-cardiac cavity.
  • 10. The method of claim 1, wherein the pattern is in accordance with a Maze procedure surrounding a port in a surface of the wall of the intra-cardiac cavity.
  • 11. The method of claim 1, further comprising causing selected ones of the elements to ablate the surface of the wall of the intra-cardiac cavity at a location determined based at least on the visual representation, the determined location located on the surface away from a respective location on the surface of the tissue wall interrupted by each of the one or more ports.
  • 12. The method of claim 1, wherein the visual representation specifies a size of each port of the one or more ports, and the method further comprises causing selected ones of the elements to ablate the surface of the wall of the intra-cardiac cavity at a location determined based at least in part on the size of each port of the one or more ports specified by the visual representation, the determined location located on the surface away from each of the one or more ports.
  • 13. The method of claim 1, further comprising causing selected ones of the elements to ablate the surface of the wall of the intra-cardiac cavity at a location other than a location of each of the one or more ports in the surface of the wall of the intra-cardiac cavity.
  • 14. The method of claim 1, wherein the ablating includes bipolar ablation.
  • 15. The method of claim 1, further comprising determining a size of a port in the wall of the intra-cardiac cavity based at least in part on temperature sensed by one or more of the elements.
  • 16. The method of claim 1, further comprising determining a location of a port in the wall of the intra-cardiac cavity based at least in part on temperature sensed by one or more of the elements.
US Referenced Citations (363)
Number Name Date Kind
4114202 Roy et al. Sep 1978 A
4164046 Cooley Aug 1979 A
4225148 Andersson Sep 1980 A
4240441 Khalil Dec 1980 A
4263680 Reul et al. Apr 1981 A
4273128 Lary Jun 1981 A
4411266 Cosman Oct 1983 A
4490859 Black et al. Jan 1985 A
4543090 McCoy Sep 1985 A
4699147 Chilson et al. Oct 1987 A
4770187 Lash et al. Sep 1988 A
4787369 Allred, III et al. Nov 1988 A
4794912 Lia Jan 1989 A
4850957 Summers Jul 1989 A
4887613 Farr et al. Dec 1989 A
4890602 Hake Jan 1990 A
4890612 Kensey Jan 1990 A
4893613 Hake Jan 1990 A
4895166 Farr et al. Jan 1990 A
4921499 Hoffman et al. May 1990 A
4940064 Desai Jul 1990 A
4942788 Farr et al. Jul 1990 A
4979514 Sekii et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5026384 Farr et al. Jun 1991 A
5047047 Yoon Sep 1991 A
5122137 Lennox Jun 1992 A
5127902 Fischell Jul 1992 A
5156151 Imram Oct 1992 A
5174299 Nelson Dec 1992 A
5176693 Pannek, Jr. Jan 1993 A
5178620 Eggers et al. Jan 1993 A
5192291 Pannek, Jr. Mar 1993 A
5195505 Josefsen Mar 1993 A
5201316 Pomeranz et al. Apr 1993 A
5228442 Imram Jul 1993 A
5242386 Holzer Sep 1993 A
5245987 Redmond et al. Sep 1993 A
5255679 Imran Oct 1993 A
5279299 Imram Jan 1994 A
5293869 Edwards et al. Mar 1994 A
5312435 Nash et al. May 1994 A
5317952 Immega Jun 1994 A
5324284 Imran Jun 1994 A
5327889 Imran Jul 1994 A
5341807 Nardella Aug 1994 A
5345936 Pomeranz et al. Sep 1994 A
5351679 Mayzels et al. Oct 1994 A
5366443 Eggers et al. Nov 1994 A
5379773 Hornsby Jan 1995 A
5397321 Houser et al. Mar 1995 A
5419767 Eggers et al. May 1995 A
5450860 O'Connor Sep 1995 A
5465717 Imran et al. Nov 1995 A
5478353 Yoon Dec 1995 A
5496267 Drasler et al. Mar 1996 A
5531760 Alwafaie Jul 1996 A
5545193 Fleischman et al. Aug 1996 A
5557967 Renger Sep 1996 A
5575810 Swanson et al. Nov 1996 A
5593424 Northrup, III Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5620481 Desai et al. Apr 1997 A
5662587 Grundfest et al. Sep 1997 A
5681308 Edwards et al. Oct 1997 A
5681336 Clement et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5687737 Branham et al. Nov 1997 A
5697285 Nappi et al. Dec 1997 A
5713896 Nardella Feb 1998 A
5713942 Stern et al. Feb 1998 A
5716397 Myers Feb 1998 A
5720726 Marcadis et al. Feb 1998 A
5728114 Evans et al. Mar 1998 A
5730127 Avitall Mar 1998 A
5762066 Law et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5782239 Webster Jul 1998 A
5782879 Rosborough et al. Jul 1998 A
5800495 Machek et al. Sep 1998 A
5823189 Kordis Oct 1998 A
5824066 Gross Oct 1998 A
5836990 Li Nov 1998 A
5868755 Kanner et al. Feb 1999 A
5876343 Teo Mar 1999 A
5881727 Edwards Mar 1999 A
5891136 McGee et al. Apr 1999 A
5904711 Flom et al. May 1999 A
5916163 Panescu et al. Jun 1999 A
5919207 Taheri Jul 1999 A
5921924 Avitall Jul 1999 A
5935075 Casscells et al. Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941251 Panescu et al. Aug 1999 A
5961440 Schweich, Jr. et al. Oct 1999 A
5968040 Swanson et al. Oct 1999 A
5984950 Cragg et al. Nov 1999 A
6001069 Tachibana et al. Dec 1999 A
6001093 Swanson et al. Dec 1999 A
6014581 Whayne et al. Jan 2000 A
6036689 Tu et al. Mar 2000 A
6063082 DeVore et al. May 2000 A
6104944 Martinelli Aug 2000 A
6106522 Fleischman et al. Aug 2000 A
6123702 Swanson et al. Sep 2000 A
6138043 Avitall Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6156046 Passafaro et al. Dec 2000 A
6210432 Solem et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6217573 Webster Apr 2001 B1
6241747 Ruff Jun 2001 B1
6248124 Pedros et al. Jun 2001 B1
6258258 Sartori et al. Jul 2001 B1
6266550 Selmon et al. Jul 2001 B1
6304769 Arenson et al. Oct 2001 B1
6306135 Ellman et al. Oct 2001 B1
6308091 Avitall Oct 2001 B1
6319249 Töllner Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6346105 Tu et al. Feb 2002 B1
6350263 Wetzig et al. Feb 2002 B1
6383151 Diederich May 2002 B1
6389311 Whayne et al. May 2002 B1
6391024 Sun et al. May 2002 B1
6391048 Ginn et al. May 2002 B1
6391054 Carpentier et al. May 2002 B2
6402781 Langberg et al. Jun 2002 B1
6436052 Nikolic et al. Aug 2002 B1
6475223 Werp et al. Nov 2002 B1
6485409 Voloshin et al. Nov 2002 B1
6485482 Belef Nov 2002 B1
6485489 Teirstein et al. Nov 2002 B2
6506210 Kanner Jan 2003 B1
6508825 Selmon et al. Jan 2003 B1
6514249 Maguire et al. Feb 2003 B1
6529756 Phan et al. Mar 2003 B1
6537198 Vidlund et al. Mar 2003 B1
6537314 Langberg et al. Mar 2003 B2
6540670 Hirata et al. Apr 2003 B1
6551312 Zhang et al. Apr 2003 B2
6569160 Goldin et al. May 2003 B1
6569198 Wilson et al. May 2003 B1
6575971 Hauck et al. Jun 2003 B2
6589208 Ewers et al. Jul 2003 B2
6626930 Allen et al. Sep 2003 B1
6632238 Ginn et al. Oct 2003 B2
6635056 Kadhiresan et al. Oct 2003 B2
6640119 Budd et al. Oct 2003 B1
6662034 Segner et al. Dec 2003 B2
6704590 Haldeman Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6726716 Marquez Apr 2004 B2
6760616 Hoey et al. Jul 2004 B2
6780197 Roe et al. Aug 2004 B2
6788969 Dupree et al. Sep 2004 B2
6797001 Mathis et al. Sep 2004 B2
6800090 Alferness et al. Oct 2004 B2
6824562 Mathis et al. Nov 2004 B2
6837886 Collins et al. Jan 2005 B2
6852076 Nikolic et al. Feb 2005 B2
6855143 Davison et al. Feb 2005 B2
6890353 Cohn et al. May 2005 B2
6892091 Ben-Haim et al. May 2005 B1
6899674 Viebach et al. May 2005 B2
6907297 Wellman et al. Jun 2005 B2
6908478 Alferness et al. Jun 2005 B2
6913576 Bowman Jul 2005 B2
6918903 Bass Jul 2005 B2
6926669 Stewart et al. Aug 2005 B1
6942657 Sinofsky et al. Sep 2005 B2
6949122 Adams et al. Sep 2005 B2
6960206 Keane Nov 2005 B2
6960229 Mathis et al. Nov 2005 B2
6986775 Morales et al. Jan 2006 B2
6989010 Francischdli et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
6994093 Murphy et al. Feb 2006 B2
6997951 Solem et al. Feb 2006 B2
7001383 Keidar Feb 2006 B2
7025776 Houser et al. Apr 2006 B1
7048734 Fleischman et al. May 2006 B1
7050848 Hoey et al. May 2006 B2
7052487 Cohn et al. May 2006 B2
7068867 Adoram et al. Jun 2006 B2
7141019 Pearlman Nov 2006 B2
7144363 Pai et al. Dec 2006 B2
7166127 Spence et al. Jan 2007 B2
7177677 Kaula et al. Feb 2007 B2
7186210 Feld et al. Mar 2007 B2
7187964 Khoury Mar 2007 B2
7189202 Lau et al. Mar 2007 B2
7276044 Ferry et al. Oct 2007 B2
7279007 Nikolic et al. Oct 2007 B2
7300435 Wham et al. Nov 2007 B2
7303526 Sharkey et al. Dec 2007 B2
7335196 Swanson et al. Feb 2008 B2
7507252 Lashinski et al. Mar 2009 B2
7530980 Hooven May 2009 B2
7736388 Goldfarb et al. Jun 2010 B2
7738967 Salo Jun 2010 B2
8103338 Harlev et al. Jan 2012 B2
8118853 Grewe Feb 2012 B2
8150499 Gelbart et al. Apr 2012 B2
8224432 MacAdam et al. Jul 2012 B2
20010003158 Kensey et al. Jun 2001 A1
20010005787 Oz et al. Jun 2001 A1
20010018611 Solem et al. Aug 2001 A1
20010020126 Swanson et al. Sep 2001 A1
20010021867 Kordis et al. Sep 2001 A1
20020002329 Avitall Jan 2002 A1
20020016628 Langberg et al. Feb 2002 A1
20020087156 Maguire et al. Jul 2002 A1
20020087173 Alferness et al. Jul 2002 A1
20020099415 Panescu et al. Jul 2002 A1
20020107478 Wendlandt Aug 2002 A1
20020107511 Collins et al. Aug 2002 A1
20020107530 Sauer et al. Aug 2002 A1
20020115941 Whayne et al. Aug 2002 A1
20020115944 Mendes et al. Aug 2002 A1
20020169504 Alferness et al. Nov 2002 A1
20020177782 Penner Nov 2002 A1
20020183836 Liddicoat et al. Dec 2002 A1
20020183841 Cohn et al. Dec 2002 A1
20020188170 Santamore et al. Dec 2002 A1
20030028118 Dupree et al. Feb 2003 A1
20030028183 Sanchez et al. Feb 2003 A1
20030050685 Nikolic et al. Mar 2003 A1
20030055420 Kadhiresan et al. Mar 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030069636 Solem et al. Apr 2003 A1
20030078465 Pai et al. Apr 2003 A1
20030078671 Lesniak et al. Apr 2003 A1
20030105384 Sharkey et al. Jun 2003 A1
20030105520 Alferness et al. Jun 2003 A1
20030109770 Sharkey et al. Jun 2003 A1
20030176810 Maahs et al. Sep 2003 A1
20030181819 Desai Sep 2003 A1
20030229395 Cox Dec 2003 A1
20040002626 Feld et al. Jan 2004 A1
20040054279 Hanley Mar 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040176797 Opolski Sep 2004 A1
20040181139 Falwell et al. Sep 2004 A1
20040186566 Hindricks et al. Sep 2004 A1
20040215232 Belhe et al. Oct 2004 A1
20040243170 Suresh et al. Dec 2004 A1
20040249408 Murphy et al. Dec 2004 A1
20040249453 Cartledge et al. Dec 2004 A1
20040267358 Reitan Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050015109 Lichtenstein Jan 2005 A1
20050054938 Wehman et al. Mar 2005 A1
20050055089 Macoviak et al. Mar 2005 A1
20050060030 Lashinski et al. Mar 2005 A1
20050064665 Han Mar 2005 A1
20050065420 Collins et al. Mar 2005 A1
20050065504 Melsky et al. Mar 2005 A1
20050080402 Santamore et al. Apr 2005 A1
20050096047 Haberman et al. May 2005 A1
20050096647 Steinke et al. May 2005 A1
20050107723 Wehman et al. May 2005 A1
20050107871 Realyvasquez et al. May 2005 A1
20050125030 Forsberg et al. Jun 2005 A1
20050148892 Desai Jul 2005 A1
20050149014 Hauck et al. Jul 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050154252 Sharkey et al. Jul 2005 A1
20050182365 Hennemann et al. Aug 2005 A1
20050187620 Pai et al. Aug 2005 A1
20050197593 Burbank et al. Sep 2005 A1
20050197692 Pai et al. Sep 2005 A1
20050197693 Pai et al. Sep 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050203558 Maschke Sep 2005 A1
20050209636 Widomski et al. Sep 2005 A1
20050216054 Widomski et al. Sep 2005 A1
20050240249 Tu et al. Oct 2005 A1
20050251116 Steinke et al. Nov 2005 A1
20050251132 Oral et al. Nov 2005 A1
20050256521 Kozee Nov 2005 A1
20050267574 Cohn et al. Dec 2005 A1
20060009755 Sra Jan 2006 A1
20060009756 Francischelli et al. Jan 2006 A1
20060014998 Sharkey et al. Jan 2006 A1
20060015002 Moaddeb et al. Jan 2006 A1
20060015003 Moaddes et al. Jan 2006 A1
20060015038 Weymarn-Scharli Jan 2006 A1
20060015096 Hauck et al. Jan 2006 A1
20060025800 Suresh Feb 2006 A1
20060030881 Sharkey et al. Feb 2006 A1
20060085049 Cory et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060100618 Chan et al. May 2006 A1
20060106298 Ahmed et al. May 2006 A1
20060135968 Schaller Jun 2006 A1
20060135970 Schaller Jun 2006 A1
20060184242 Lichtenstein Aug 2006 A1
20060199995 Vijay Sep 2006 A1
20060229491 Sharkey et al. Oct 2006 A1
20060235286 Stone et al. Oct 2006 A1
20060235314 Migliuolo et al. Oct 2006 A1
20060264980 Khairkhahan et al. Nov 2006 A1
20060281965 Khairkhahan et al. Dec 2006 A1
20060293698 Douk Dec 2006 A1
20060293725 Rubinsky et al. Dec 2006 A1
20070016068 Grunwald et al. Jan 2007 A1
20070027533 Douk Feb 2007 A1
20070038208 Kefer Feb 2007 A1
20070083193 Werneth et al. Apr 2007 A1
20070083195 Werneth et al. Apr 2007 A1
20070088362 Bonutti et al. Apr 2007 A1
20070115390 Makara et al. May 2007 A1
20070118215 Moaddeb May 2007 A1
20070129717 Brown, III et al. Jun 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070198058 Gelbart et al. Aug 2007 A1
20070213578 Khairkhahan et al. Sep 2007 A1
20070213815 Khairkhahan et al. Sep 2007 A1
20070232858 Macnamara et al. Oct 2007 A1
20070249999 Sklar et al. Oct 2007 A1
20070270688 Gelbart et al. Nov 2007 A1
20070299343 Waters Dec 2007 A1
20080004534 Gelbart et al. Jan 2008 A1
20080004643 To et al. Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080045778 Lichtenstein et al. Feb 2008 A1
20080071298 Khairkhahan et al. Mar 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080312713 Wilfley et al. Dec 2008 A1
20090018617 Skelton et al. Jan 2009 A1
20090069704 MacAdam et al. Mar 2009 A1
20090131930 Gelbart May 2009 A1
20090157058 Ferren et al. Jun 2009 A1
20090192441 Gelbart et al. Jul 2009 A1
20090270737 Thornton Oct 2009 A1
20090287271 Blum et al. Nov 2009 A1
20090287304 Dahlgren et al. Nov 2009 A1
20100121147 Oskin et al. May 2010 A1
20100211052 Brown et al. Aug 2010 A1
20100249771 Pearson et al. Sep 2010 A1
20100268059 Ryu et al. Oct 2010 A1
20110125172 Gelbart et al. May 2011 A1
20110172658 Gelbart et al. Jul 2011 A1
20110282491 Prisco et al. Nov 2011 A1
20120158016 Gelbart et al. Jun 2012 A1
20120165829 Chen et al. Jun 2012 A1
20120271135 Burke et al. Oct 2012 A1
20130172883 Lopes et al. Jul 2013 A1
20130178850 Lopes et al. Jul 2013 A1
20130178851 Lopes et al. Jul 2013 A1
20130184705 Gelbart et al. Jul 2013 A1
20130184706 Gelbart et al. Jul 2013 A1
20130190587 Lopes et al. Jul 2013 A1
20130197513 Lopes et al. Aug 2013 A1
20130304065 Lopes et al. Nov 2013 A1
20140114307 Moisa et al. Apr 2014 A1
20140350552 Highsmith Nov 2014 A1
Foreign Referenced Citations (25)
Number Date Country
101797181 Aug 2010 CN
0723467 Apr 2002 EP
9510320 Apr 1995 WO
9520349 Aug 1995 WO
9717892 May 1997 WO
0108575 Feb 2001 WO
03015611 Feb 2003 WO
03077800 Sep 2003 WO
2004012629 Feb 2004 WO
2004047679 Jun 2004 WO
2004084746 Oct 2004 WO
2004100803 Nov 2004 WO
2005070330 Aug 2005 WO
2005102181 Nov 2005 WO
2006017809 Feb 2006 WO
2006105121 Oct 2006 WO
2006135747 Dec 2006 WO
2006135749 Dec 2006 WO
2007021647 Feb 2007 WO
2007115390 Oct 2007 WO
2008002606 Jan 2008 WO
2009065042 May 2009 WO
2012100184 Jul 2012 WO
2012100185 Jul 2012 WO
2013173917 Nov 2013 WO
Non-Patent Literature Citations (95)
Entry
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Notice of Allowance mailed Nov. 13, 2014 for U.S. Appl. No. 13/070,215, 54 pages.
Official Action issued in CN201280004400.9, mailed Dec. 3, 2014.
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Oct. 22, 2013 for co-pending U.S. Appl. No. 13/942,354, 13 pgs.
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Mar. 14, 2013 for co-pending U.S. Appl. No. 13/782,867, 8 pgs.
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Aug. 20, 2014 for co-pending U.S. Appl. No. 13/782,889, 11 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,305, 12 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,250, 10 pgs.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Pre Amend filed Aug. 29, 2007 for U.S. Appl. No. 11/475,950, 42 pgs.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Aug. 16, 2010 for U.S. Appl. No. 11/475,950, 22 pgs.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Mar. 5, 2008 for U.S. Appl. No. 11/475,950, 11 pgs.
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Feb. 23, 2011 for U.S. Appl. No. 11/475,950, 28 pgs.
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Remarks filed Mar. 5, 2013 for co-pending U.S. Appl. No. 13/785,931, 10 pgs.
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Amendment filed Mar. 5, 2013 for co-pending U.S. Appl. No. 13/785,910, 10 pgs.
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed Apr. 10, 2014; Supplemental Amendment filed Feb. 12, 2013 for co-pending U.S. Appl. No. 11/475,950, 21 pgs.
Non-Final Office Action issued in co-pending U.S. Appl. No. 13/782,867, dated Apr. 15, 2015.
Non-final Office Action issued in co-pending U.S. Appl. No. 13/782,903, dated Apr. 28, 2015.
Sharkey et al., “Left Ventricular Apex Occluder. Description of a Ventricular Partitioning Device,” EuroIntervention 2:125-127,2006.
Stiles, et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance,” IEE Transactions on Biomedical Engineering, 50(7):916-921, 2003.
Tanaka et al., “Artificial SMA Valve for Treatment of Urinary Incontinence: Upgrading of Valve and Introduction of Transcutaneous TranSformer,” Bio-Medical Materials and Engineering 9:97-112,1999.
Timek et al., “Septal-Lateral Annular Cinching (‘SLAC’) Reduces Mitral Annular Size Without Perturbing Normal Annular Dynamics,” Journal of Heart Valve Disease 11 (1 ):2-10, 2002.
Timek et al., “Septal-Lateral Annular Cinching Abolishes Acute Ischemic Mitral Regurgitation,” Journal of Thoracic and Cardiovascular Surgery, 123(5):881-888, 2002.
Valvano et al., “Thermal Conductivity and Diffusivity of Biomaterials Measured with Self-Heated Thermistors,” International Journal of Thermodynamics, 6(3):301-311, 1985.
Written Opinion, mailed Dec. 5, 2007, for PCT/US2007/014902, 7 pages.
Written Opinion, mailed Dec. 2, 2009, for PCT/US2008/083644, 9 pages.
De Ponti et al., “Non-Fluoroscopic Mapping Systems for Electrophysiology: The ‘Tool or Toy’ Dilemma After 10 Years,” European Heart Journal 27:1134-1136, 2006.
Gabriel et al., “The Dielectric Properties of Biological Tissues: I. Literature Survey,” Phys. Med. Biol. 41 :2231-2249, 1996.
Lichtenstein, “Method and Apparatus for Percutaneous Reduction of Anterior-Posterior Diameter of Mitral Valve,” U.S. Appl. No. 10/690,131, filed Oct. 20, 2003, 31 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Aug. 4, 2009 for U.S. Appl. No. 11/436,584, 35 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Mar. 30, 2010 for U.S. Appl. No. 11/436,584, 20 pages.
Gelbart et al., “Automatic Atherectomy System,” Amendment filed Oct. 25, 2010 for U.S. Appl. No. 11/436,584, 9 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action mailed Dec. 14, 2010 for U.S. Appl. No. 11/436,584, 12 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action mailed Jun. 15, 2011, for U.S. Appl. No. 12/950,871, 16 pages.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium,” Office Action mailed Jul. 25, 2011 for U.S. Appl. No. 11/941,819, 9 pages.
Gelbart et al., “Liposuction System,” Office Action mailed Mar. 16, 2011 for U.S. Appl. No. 12/010,458, 12 pages.
Gelbart et al., “Liposuction System,” Amendment filed Jun. 10, 2011 for U.S. Appl. No. 12/010,458, 10 pages.
Becker, “Ablation of Atrial Fibrillation: Energy Sources and Navigation Tools: A Review”, J. of Electrocardiology, vol. 37, Supp 2004, pp. 55-62.
Calkins, “Radiofrequency Catheter Ablation of Supraventricular Arrhythmias”, Heart 2001; 85, 594-600.
Non-final Office Action issued in U.S. Appl. No. 11/475,950, dated Jun. 23, 2010.
Final Office Action issued in U.S. Appl. No. 11/475,950, dated Nov. 23, 2010.
Non-final Office Action issued in U.S. Appl. No. 11/475,950, dated Dec. 13, 2013.
Notice of Allowance issued in U.S. Appl. No. 11/475,950, dated Jul. 25, 2014.
Notice of Allowance issued in U.S. Appl. No. 11/475,950, dated Oct. 23, 2014.
“Phased RF Catheter Ablation System”, 2014 Medtronic Inc., 2 pgs, http://www.medtronic.eu/your-health/atrial-fibrillation/about-the-therapy/our-phased-rf-ablation-system/[Jun. 24, 2014 2:38:05 PM].
“ThermoCool® Irrigated Tip Catheter”, Brochure, Biosense Webster, 4 pgs, Biosense Webster, Inc. 3333 Diamond Canyon Road Diamond Bar, CA 91765, USA, © Biosense Webster, Inc. 2009 All rights reserved. 1109003.0.
Biotronik's “AlCath Flutter Gold Cath for Atrial Flutter Available in EU”, medGadget, 3 pgs, http://www.medgadget.com/2013/09/biotroniks-alcath-flutter-gold-cath-for-atrial-flutter-unveiled-in-europe.html[Jun. 24, 2014 2:37:09 PM].
Extended European Search Report and EP search opinion for EP 12736677.1, mail date of Mar. 28, 2014, corresponding to PCT/US2012/022061.
Extended European Search Report and EP search opinion for EP 12736962.7, mail date of Mar. 28, 2014, corresponding to PCT/US2012/022062.
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Oct. 25, 2010 for U.S. Appl. No. 11/436,584, 9 pgs.
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Mar. 30, 2010 for U.S. Appl. No. 11/436,584, 20 pgs.
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Aug. 4, 2009 for U.S. Appl. No. 11/436,584, 35 pgs.
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Sep. 15, 2011 for U.S. Appl. No. 12/950,871, 21 pgs.
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Jun. 15, 2011 for U.S. Appl. No. 12/950,871, 16 pgs.
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Dec. 1, 2009 for U.S. Appl. No. 11/436,584, 8 pgs.
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Dec. 14, 2010 for U.S. Appl. No. 11/436,584, 12 pgs.
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Mar. 4, 2009 for U.S. Appl. No. 11/436,584, 6 pgs.
Bard, “HD Mesh Ablator Catheter”, Brochure, 2008, 4 pgs, Bard Electrophysiology Division, C.R. Bard Inc., 55 Technology Drive Lowell, MA 01851 USA.
“Constellation Mapping Catheters”, Brochure, Boston Scientific Corp., 2 pgs, © 2007 Boston Scientific Corporation.
Written opinion dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs.
Written opinion dated Aug. 22, 2012 for PCT/US2012/022061, 6 pgs.
International Search Report dated Aug. 22, 2012 for PCT/US2012/022061, 5 pgs.
International Search Report dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action mailed Jul. 25, 2011 for U.S. Appl. No. 11/941,819, now published as US 2009-0131930 A1.
Gelbart et al., “Liposuction System”, Amendment filed Jun. 10, 2011 for U.S. Appl. No. 12/010,458, 10 pgs.
Gelbart et al., “Liposuction System”, Amendment filed Dec. 7, 2011 for U.S. Appl. No. 12/010,458, 15 pgs.
Gelbart et al., “Liposuction System”, Office Action mailed Mar. 16, 2011 for U.S. Appl. No. 12/010,458, 12 pgs.
Gelbart et al., “Liposuction System”, Office Action mailed Sep. 14, 2011 for U.S. Appl. No. 12/010,458, 9 pgs.
“Waveforms and Segments”, Ensite System Instructions for use, 54-06154-001 Rev02, Chapter 7 , pp. 85-90 © 2007 St. Jude Medical.
International Search Report and Written Opinion mailed Aug. 2, 2013 issued in PCT/CA2013/050350.
International Search Report and Written Opinion mailed Sep. 17, 2013 issued in PCT/US2013/039982.
International Search Report and Written Opinion mailed Sep. 27, 2013 issued in PCT/US2013/039977.
Extended European Search Report mailed Aug. 20, 2013 issued in EP Patent Application No. 13172848.7.
Ensite System Instructions for use, 54-06154-001 Rev02, Chapter 7 Waveforms and Segments, pp. 85-90.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Jul. 3, 2014 for U.S. Appl. No. 11/941,819, 10 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Apr. 2, 2012 for U.S. Appl. No. 11/941,819, 24 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Mar. 1, 2012 for U.S. Appl. No. 11/941,819, 23 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Nov. 23, 2011 for U.S. Appl. No. 11/941,819, 17 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Replacement drawings filed Feb. 13, 2008 for U.S. Appl. No. 11/941,819, 6 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action dated Jan. 3, 2012 for co-pending U.S. Appl. No. 11/941,819, 19 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action dated Apr. 3, 2014 for co-pending U.S. Appl. No. 11/941,819, 17 pgs.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Notice of Allowance dated Aug. 26, 2014 for co-pending U.S. Appl. No. 11/941,819, 19 pages.
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Supplemental Notice of Allowance dated Oct. 6, 2014 for co-pending U.S. Appl. No. 11/941,819, 4 pgs.
Gelbart et al., Medical Device for Use in Bodily Lumens, for Example an Atrium, Amendment filed Sep. 22, 2014, for co-pending U.S. Appl. No. 13/070,215, 18 pgs.
Gelbart et al., Medical Device for Use in Bodily Lumens, for Example an Atrium, Office Action dated Jun. 20, 2014, for co-pending U.S. Appl. No. 13/070,215, 8 pgs.
Buchbinder, Maurice, MD, “Dynamic Mitral Valve Annuloplasty: A Reshapable Ring for Residual and Recurring MR,” from the Foundation for Cardiovascular Medicine, La Jolla, CA. May 24, 2007.
Gelbart et al., “Automatic Atherectomy System,” Office Action mailed Mar. 4, 2009 for U.S. Appl. No. 11/436,584,7 pages.
Gelbart et al., “Automatic Atherectomy System,” Office Action mailed Dec. 1, 2009 for U.S. Appl. No. 11/436,584, 10 pages.
International Search Report, mailed Dec. 5, 2007, for PCT/US2007/014902, 5 pages.
International Search Report, mailed Dec. 2, 2009, for PCT/US2008/083644, 5 pages.
International Preliminary Report on Patentability, issued Jan. 6, 2009, for PCT/US2007/014902, 8 pages.
Konings et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries,” IEEE Transactions on Medical Imaging, 16(4):439-446, 1997.
Mack, “New Techniques for Percutaneous Repair of the Mitral Valve,” Heart Failure Review, 11 :259-268, 2006.
Otasevic et al., “First-in-Man Implantation of Left Ventricular Partitioning Device in a Patient With Chronic Heart Failure: Twelve-Month Follow-up,” Journal of Cardiac Failure 13(7):517-520, 2007.
International Search Report mailed Mar. 10, 2015, for International Application PCT/CA2014/051144; 10 pages.
Written Opinion mailed Mar. 10, 2015, for International Application PCT/CA2014/051144; 4 pages.
Biotronik's “AlCath Flutter Gold Cath for Atrial Flutter Available in EU”, Sep. 19, 2013, medGadget, 3 pgs, http://www.medgadget.com/2013/09/biotroniks-alcath-flutter-gold-cath-for-atrial-flutter-unveiled-in-europe.html [Jun. 24, 2014 2:37:09 PM].
Related Publications (1)
Number Date Country
20150126993 A1 May 2015 US
Continuations (1)
Number Date Country
Parent 11475950 Jun 2006 US
Child 14546542 US